Complete remission of psoriasis following bevacizumab therapy for colon cancer

Akman, Ayşe; Yılmaz, Ertan; Mutlu, Hasan; Özdoğan, Mustafa

doi:10.1111/j.1365-2230.2008.02991.x

Cited by 67 publications

(53 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, there is some clinical evidence of complete remission of psoriasis following anti-VEGF treatment [39]. Akman et al reported a patient with psoriasis (showing an initial Psoriasis Area and Severity Index -PASI -of 16.8) who had complete remission of psoriasis during bevacizumab (monoclonal antibody against VEGF) therapy for colon cancer.…”

Section: Vegf As a Target For Psoriasis Treatmentmentioning

confidence: 98%

Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—A possible target for novel therapies?

Canavese

Altruda

Ruzicka

et al. 2010

Journal of Dermatological Science

View full text Add to dashboard Cite

Section: Vegf As a Target For Psoriasis Treatmentmentioning

confidence: 98%

Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—A possible target for novel therapies?

Canavese

Altruda

Ruzicka

et al. 2010

Journal of Dermatological Science

View full text Add to dashboard Cite

“…Moreover, the prominent involvement of angiogenesis in the pathogenesis of psoriasis and the validated use of anti-angiogenic therapy in human cancers using a monoclonal antibody directed against VEGF (bevacizumab, Avastin R ) (17, 18) suggests anti-VEGF treatment as a possible therapy for patients suffering from psoriasis. Recently, a patient was reported to experience complete remission of psoriasis during bevacizumab treatment of metastatic colon cancer (19).…”

mentioning

confidence: 99%

Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis

Schönthaler

Huggenberger

Wculek

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

128

View full text Add to dashboard Cite

Although , vascular remodeling is a hallmark of many chronic inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis, anti-vascular strategies to treat these conditions have received little attention to date. We investigated the anti-inflammatory activity of systemic blockade of VEGF-A by the inhibitory monoclonal antibody G6 -31, employing a therapeutic trial in a mouse model of psoriasis. Simultaneous deletion of JunB and c-Jun (DKO*) in the epidermis of adult mice leads to a psoriasis-like phenotype with hyper-and parakeratosis and increased subepidermal vascularization. Moreover, an inflammatory infiltrate and elevated levels of cytokines/chemokines including TNF␣, IL-1␣/␤, IL-6, and the innate immune mediators IL-22, IL-23, IL-23R, and IL-12p40 are detected. Here we show that anti-VEGF antibody treatment of mice already displaying disease symptoms resulted in an overall improvement of the psoriatic lesions leading to a reduction in the number of blood vessels and a significant decrease in the size of dermal blood and lymphatic vessels. Importantly, anti-VEGF-treated mice showed a pronounced reduction of inflammatory cells within the dermis and a normalization of epidermal differentiation. These results demonstrate that systemic blockade of VEGF by an inhibitory antibody might be used to treat patients who have inflammatory skin disorders such as psoriasis.activator protein-1 ͉ Jun proteins ͉ epidermis ͉ angiogenesis ͉ G6-31 antibody

show abstract

“…However, direct evidence to corroborate this hypothesis is still scant. A VEGF-directed antibody led to complete remission of psoriasis in 1 patient (55). In addition, several transgenic mouse models have been generated to clarify whether angiogenesis-related factors can initiate psoriasiform pathologies (40).…”

Section: Discussionmentioning

confidence: 99%

Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions

Zibert

Wallbrecht²,

Schön³

et al. 2011

J. Clin. Invest.

View full text Add to dashboard Cite

Dysregulated angiogenesis is a hallmark of chronic inflammatory diseases, including psoriasis, a common skin disorder that affects approximately 2% of the population. Studying both human psoriasis in 2 complementary xenotransplantation models and psoriasis-like skin lesions in transgenic mice with epidermal expression of human TGF-β1, we have demonstrated that antiangiogenic non-viral somatic gene therapy reduces the cutaneous microvasculature and alleviates chronic inflammatory skin disorders. Transient muscular expression of the recombinant disintegrin domain (RDD) of metargidin (also known as ADAM-15) by in vivo electroporation reduced cutaneous angiogenesis and vascularization in all 3 models. As demonstrated using red fluorescent protein-coupled RDD, the treatment resulted in muscular expression of the gene product and its deposition within the cutaneous hyperangiogenic connective tissue. High-resolution ultrasound revealed reduced cutaneous blood flow in vivo after electroporation with RDD but not with control plasmids. In addition, angiogenesis-and inflammation-related molecular markers, keratinocyte proliferation, epidermal thickness, and clinical disease scores were downregulated in all models. Thus, non-viral antiangiogenic gene therapy can alleviate psoriasis and may do so in other angiogenesis-related inflammatory skin disorders.

show abstract

Complete remission of psoriasis following bevacizumab therapy for colon cancer

Cited by 67 publications

References 8 publications

Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—A possible target for novel therapies?

Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—A possible target for novel therapies?

Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis

Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions

Contact Info

Product

Resources

About